BioSystems International ("BSI") is a French biotechnology company
with research laboratories in France (Genopole Evry) and Hungary
(University of Debrecen). BSI's business is focused on the discovery
and diagnostic development of biomarkers, based on its proprietary
high throughput monoclonal antibody technology.
Prior to joining BSI, Jean Pierre Tirouflet was Chairman and CEO
of the French specialty chemicals company Rhodia. He was Chief
Financial Officer of Rhone Poulenc from 1986 to 1997 and member of its
Executive Board from 1990 to 1999. Mr Tirouflet has been Chairman of
the CEFIC (European Chemical Industry Council) from 2002 to 2004.
Formerly, he worked for the French Ministry of Finances, the
French Representation to the EEC and the Credit National . He is a
graduate of France's Ecole Nationale d'Administration.
About BioSystems International:
The mission of BioSystems International is to bring biomarkers to
the bedside.
BioSystems International is a biotechnology company and is the
industry leader in monoclonal antibody mediated biomarker discovery
and diagnostics development. Its leading position in the field is
secured by a proprietary, high throughput monoclonal antibody based
platform that achieves biomarker discovery and the first level of
validation in one step. It aims at bringing biomarkers to the bedside
in record time and at delivering integrated and new companion
diagnostics for the chronic diseases and cancer markets
BSI was founded in May 2004 by four internationally recognized
American scientists, the Professors Barry Karger and William Hancock
of Northeastern University of Boston, Professor Andras Guttman and Dr.
Laszlo Takacs. Until May 2004, Dr. Takacs was Head of Pfizer's former
Fresnes Genomic and Bioinformatics laboratories. BSI's core research
team is staffed with scientists from Dr. Takacs' prior Pfizer Fresnes
group.
Since its founding, BSI has been principally financed by Societe
Generale Asset Management by a grant from the Hungarian Ministry of
Education.. www.biosys-intl.com
